Pharmabiz3h
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...
Pharmabiz8h
Vitonnix UK joins SEARCH Foundation in its mission to target the vitamin D deficiency endemic in rural India
Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...
Pharmabiz5h
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel: Boulder, Colorado Wednesday, November 13, 2024, 16:00 Hrs [IST] Sonoma Pharmaceuticals, Inc.
Pharmabiz21h
Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis
Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, announced an interim data readout of the phase 1/2a studies of Radspherin for the treatment ...
Pharmabiz4h
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...
Pharmabiz23h
Neurizon Therapeutics receives positive opinion on orphan medicinal product designation for NUZ-001 in Europe
Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European ...
Pharmabiz5h
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...
Pharmabiz22h
ALIGNMT AI & HFMA collaborate to offer AI governance micro-credentialing for healthcare professionals
ALIGNMT AI, a leading provider of software solutions for AI governance and compliance, announced a strategic collaboration with the Healthcare Financial Management Association (HFMA) to launch a ...
Pharmabiz8h
Merck to present new data from Gardasil 9 studies reinforcing the importance of gender-neutral HPV vaccination in adults up to age 45 at IPVC 2024
Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...
Pharmabiz3h
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...
Pharmabiz31m
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1
Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, ...
Pharmabiz1d
EnteroBiotix reports positive results from phase 1b IMPuLCE study of EBX-102 in liver cirrhosis
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...